Nanoplasmonic biosensors for multicolor visual analysis of acetylcholinesterase activity and drug inhibitor screening in point-of-care testing
Biosens Bioelectron. 2023 Dec 8;247:115912. doi: 10.1016/j.bios.2023.115912. Online ahead of print.ABSTRACTThe monitoring of acetylcholinesterase (AChE) activity and the screening of its inhibitors are significance of the diagnosis and drug therapy of nervous diseases. A metal ions-mediated signal amplification strategy was developed for the highly sensitive and multicolor assay of AChE activity and visually screening its drug inhibitors. After the specific reaction between AChE and acetylthiocholine (ATCh), the hydrolysis product thiocholine (TCh) can directly and decompose the α-FeOOH nanorods (NRs) to release amounts o...
Source: Biosensors and Bioelectronics - December 14, 2023 Category: Biotechnology Authors: De Yan Li Lu Chen Cai Yan Li Jin Zhang Yan Zhao Yun Hui Yang Tong Yang Source Type: research
Nanoplasmonic biosensors for multicolor visual analysis of acetylcholinesterase activity and drug inhibitor screening in point-of-care testing
Biosens Bioelectron. 2023 Dec 8;247:115912. doi: 10.1016/j.bios.2023.115912. Online ahead of print.ABSTRACTThe monitoring of acetylcholinesterase (AChE) activity and the screening of its inhibitors are significance of the diagnosis and drug therapy of nervous diseases. A metal ions-mediated signal amplification strategy was developed for the highly sensitive and multicolor assay of AChE activity and visually screening its drug inhibitors. After the specific reaction between AChE and acetylthiocholine (ATCh), the hydrolysis product thiocholine (TCh) can directly and decompose the α-FeOOH nanorods (NRs) to release amounts o...
Source: Biosensors and Bioelectronics - December 14, 2023 Category: Biotechnology Authors: De Yan Li Lu Chen Cai Yan Li Jin Zhang Yan Zhao Yun Hui Yang Tong Yang Source Type: research
Comparative Bioavailability study of a Novel Multi-day Patch Formulation of Rivastigmine (twice weekly) with Exelon ® Transdermal Patch (daily). A randomized clinical trial
CONCLUSION: Bioequivalence was demonstrated between RID-TDS mg twice a week and Exelon® once a day in SS. Patch adhesion favored RID-TDS despite the longer dosing interval. Both products were well tolerated.TRIAL REGISTRATION NUMBER: Protocols are registered in ClinicalTrials.gov: NCT03659435 and EudraCT: 2018-001570-18.PMID:36017827 | DOI:10.2174/1567205019666220823105059 (Source: Current Alzheimer Research)
Source: Current Alzheimer Research - August 26, 2022 Category: Neurology Authors: Bjoern Schurad Cornelius Koch Barbara Schug Adelaida Morte Anna Vaqu é Rafael De la Torre Marc Iniesta Source Type: research
Comparative Bioavailability study of a Novel Multi-day Patch Formulation of Rivastigmine (twice weekly) with Exelon ® Transdermal Patch (daily). A randomized clinical trial
CONCLUSION: Bioequivalence was demonstrated between RID-TDS mg twice a week and Exelon® once a day in SS. Patch adhesion favored RID-TDS despite the longer dosing interval. Both products were well tolerated.TRIAL REGISTRATION NUMBER: Protocols are registered in ClinicalTrials.gov: NCT03659435 and EudraCT: 2018-001570-18.PMID:36017827 | DOI:10.2174/1567205019666220823105059 (Source: Current Alzheimer Research)
Source: Current Alzheimer Research - August 26, 2022 Category: Neurology Authors: Bjoern Schurad Cornelius Koch Barbara Schug Adelaida Morte Anna Vaqu é Rafael De la Torre Marc Iniesta Source Type: research
Comparative Bioavailability study of a Novel Multi-day Patch Formulation of Rivastigmine (twice weekly) with Exelon ® Transdermal Patch (daily). A randomized clinical trial
CONCLUSION: Bioequivalence was demonstrated between RID-TDS mg twice a week and Exelon® once a day in SS. Patch adhesion favored RID-TDS despite the longer dosing interval. Both products were well tolerated.TRIAL REGISTRATION NUMBER: Protocols are registered in ClinicalTrials.gov: NCT03659435 and EudraCT: 2018-001570-18.PMID:36017827 | DOI:10.2174/1567205019666220823105059 (Source: Current Alzheimer Research)
Source: Current Alzheimer Research - August 26, 2022 Category: Neurology Authors: Bjoern Schurad Cornelius Koch Barbara Schug Adelaida Morte Anna Vaqu é Rafael De la Torre Marc Iniesta Source Type: research
Comparative Bioavailability study of a Novel Multi-day Patch Formulation of Rivastigmine (twice weekly) with Exelon ® Transdermal Patch (daily). A randomized clinical trial
CONCLUSION: Bioequivalence was demonstrated between RID-TDS mg twice a week and Exelon® once a day in SS. Patch adhesion favored RID-TDS despite the longer dosing interval. Both products were well tolerated.TRIAL REGISTRATION NUMBER: Protocols are registered in ClinicalTrials.gov: NCT03659435 and EudraCT: 2018-001570-18.PMID:36017827 | DOI:10.2174/1567205019666220823105059 (Source: Current Alzheimer Research)
Source: Current Alzheimer Research - August 26, 2022 Category: Neurology Authors: Bjoern Schurad Cornelius Koch Barbara Schug Adelaida Morte Anna Vaqu é Rafael De la Torre Marc Iniesta Source Type: research
Comparative Bioavailability study of a Novel Multi-day Patch Formulation of Rivastigmine (twice weekly) with Exelon ® Transdermal Patch (daily). A randomized clinical trial
CONCLUSION: Bioequivalence was demonstrated between RID-TDS mg twice a week and Exelon® once a day in SS. Patch adhesion favored RID-TDS despite the longer dosing interval. Both products were well tolerated.TRIAL REGISTRATION NUMBER: Protocols are registered in ClinicalTrials.gov: NCT03659435 and EudraCT: 2018-001570-18.PMID:36017827 | DOI:10.2174/1567205019666220823105059 (Source: Current Alzheimer Research)
Source: Current Alzheimer Research - August 26, 2022 Category: Neurology Authors: Bjoern Schurad Cornelius Koch Barbara Schug Adelaida Morte Anna Vaqu é Rafael De la Torre Marc Iniesta Source Type: research
Bioavailability Study of a Transdermal Patch Formulation of Rivastigmine Compared with Exelon in Healthy Subjects
ConclusionsFor both products, bioequivalence was shown and systemic tolerability was in accordance with the safety profile of the drug substance.The trial is registered in ClinicalTrials.gov: NCT03573050 and EudraCT: 2018-000968-28. (Source: European Journal of Drug Metabolism and Pharmacokinetics)
Source: European Journal of Drug Metabolism and Pharmacokinetics - June 13, 2022 Category: Drugs & Pharmacology Source Type: research
Synthesis and characterization of a novel molecularly imprinted polymer for the controlled release of Rivastigmine Tartrate
Publication date: Available online 24 June 2021Source: Materials Science and Engineering: CAuthor(s): Seyed Javad Torabi, Alireza Mohebali, Majid Abdouss, Mohamadreza Shakiba, Hamidreza Abdouss, Seeram Ramakrishna, Ying Shen Teo, Iman Jafari, Erfan Rezvani Ghomi (Source: Materials Science and Engineering: C)
Source: Materials Science and Engineering: C - June 25, 2021 Category: Materials Science Source Type: research
Multisite transcranial direct current stimulation associated with cognitive training in episodic memory and executive functions in individuals with Alzheimer ’s disease: a case report
ConclusionsThe results from the two presented cases show that multisite transcranial stimulation associated with cognitive training is an effective adjuvant method for the treatment of patients diagnosed with mild Alzheimer ’s disease. Its effects can benefit patients’ daily routines by reducing cognitive deficits by keeping intact areas active and/or compensating for lost functions.Trial registration NCT02772185. Registered 13 May 2016,http://www.clinicaltrials.gov/ct2/show/NCT02772185. Retrospectively registered. (Source: Journal of Medical Case Reports)
Source: Journal of Medical Case Reports - April 22, 2021 Category: General Medicine Source Type: research
Probing the interaction of Rivastigmine Tartrate, an important Alzheimer's drug, with serum albumin: Attempting treatment of Alzheimer's disease.
Abstract
The present study was aimed at investigating the binding between an important drug of Alzheimer's therapy, Rivastigmine tartrate (RT), with Bovine serum albumin (BSA). BSA is a model protein that is increasingly being used for studies related to drug-protein interaction owing to its structural similarity with human serum albumin (HSA) which is extremely abundant in the circulatory system comprising around 60% of the total plasma protein. Fluorescence spectroscopy implied that complex formation is taking place between BSA and RT; binding constant calculated was of the order of 104 M-1 implicative...
Source: International Journal of Biological Macromolecules - January 15, 2020 Category: Biochemistry Authors: Shamsi A, Mohammad T, Anwar S, Alajmi MF, Hussain A, Hassan MI, Ahmad F, Islam A Tags: Int J Biol Macromol Source Type: research
In Vitro and in Vivo Optimization of Phase Sensitive Smart Polymer for Controlled Delivery of Rivastigmine for Treatment of Alzheimer ’s Disease
ConclusionThe results exemplify an easily injectable controlled release formulation of rivastigmine prepared using phase-sensitive smart polymer. The optimized formulation significantly increases the dosing interval, and can potentially improve patient compliance as well as quality of life of patients living with Alzheimer ’s disease. (Source: Pharmaceutical Research)
Source: Pharmaceutical Research - January 14, 2020 Category: Drugs & Pharmacology Source Type: research
Comparison Table: Drugs for Alzheimer's Disease (online only)
Date: September 25, 2017
Issue #:
1530Summary:
View the Comparison Table: Drugs for Alzheimer ' s Disease (Source: The Medical Letter)
Source: The Medical Letter - September 19, 2017 Category: Drugs & Pharmacology Authors: admin Tags: Alzheimer ' s disease Aricept Donepezil Exelon Galantamine Memantine Namenda Namzaric Parkinson Razadyne Rivastigmine Source Type: research
Comparison Table: Drugs for Alzheimer's Disease
Date: September 25, 2017
Issue #:
1530Summary:
View the Comparison Table: Drugs for Alzheimer ' s Disease (Source: The Medical Letter)
Source: The Medical Letter - September 19, 2017 Category: Drugs & Pharmacology Authors: admin Tags: Alzheimer ' s disease Aricept Donepezil Exelon Galantamine Memantine Namenda Namzaric Parkinson Razadyne Rivastigmine Source Type: research
